

## LIST OF TABLES

<b>Table 3.1</b> Demographic characteristics of hypothyroidism patients and controls. ....	36
<b>Table 4.1</b> Primers used for genotyping of <i>CTLA4</i> and <i>TG</i> SNPs and gene expression analysis.....	47
<b>Table 4.2</b> Association studies for <i>CTLA4</i> gene exon 1 +49A/G and 3'UTR CT60A/G polymorphisms and <i>TG</i> gene exon 33 polymorphism in autoimmune hypothyroidism patients. ....	52
<b>Table 4.3</b> Association of <i>CTLA4</i> exon1 +49A/G, 3' UTR CT60A/G and <i>TG</i> exon33 with autoimmune hypothyroidism when adjusted for age and gender using logistic regression. ....	53
<b>Table 4.4</b> Distribution of haplotypes frequencies for <i>CTLA4</i> gene polymorphisms (+49A/G and CT60A/G) among autoimmune hypothyroidism patients and controls.	56
<b>Table 5.1</b> Primers used for genotyping of pAL119-mCTLA4-IGHG1 expression analysis.....	85
<b>Table 5.2</b> Experimental design for evaluating efficacy of $\omega$ -amino-OA-PEI and pAL119-mCTLA4-IGHG1 polyplexes in treatment and prevention of autoimmune thyroiditis. ....	87
<b>Table 5.3</b> Assignments of chemical shift to functional group protons in <sup>1</sup> H NMR spectra for PEI 10KDa. ....	92
<b>Table 5.4</b> Extent of HA, OA, $\omega$ -amino-HA and $\omega$ -amino-OA substitution on PEI represented as % substitution based on <sup>1</sup> H-NMR analysis. ....	96
<b>Table 5.5</b> pAL119-mCTLA4-IGHG1 plasmid Description.....	100
<b>Table 5.6</b> pEGFP-N1 Plasmid vector Description. ....	103